These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26392488)

  • 21. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.
    Alm RA; McLaughlin RE; Kos VN; Sader HS; Iaconis JP; Lahiri SD
    J Antimicrob Chemother; 2014 Aug; 69(8):2065-75. PubMed ID: 24777906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage.
    Khan A; Rivas LM; Spencer M; Martinez R; Lam M; Rojas P; Porte L; Silva F; Braun S; Valdivieso F; Mv Lhauser M; Lafourcade M; Miller WR; García P; Arias CA; Munita JM
    J Clin Microbiol; 2019 Sep; 57(9):. PubMed ID: 31315958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
    Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K
    J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy of Ceftaroline with Linezolid against Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus.
    Hafeez A; Munir T; Rehman S; Najeeb S; Gilani M; Latif M; Ansari M; Saad N
    J Coll Physicians Surg Pak; 2015 Apr; 25(4):247-9. PubMed ID: 25899187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vitro activity of ceftaroline to MRSA isolates: a multicenter study].
    Mengeloğlu FZ; Taş T; Koçoğlu E; Copur Çiçek A; Yanık K; Güneş H; Ciftci IH; Durmaz S; Bucak O; Güçkan R; Terzi HA; Yavuz MZ
    Mikrobiyol Bul; 2013 Oct; 47(4):677-83. PubMed ID: 24237436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.
    Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
    Chan LC; Basuino L; Diep B; Hamilton S; Chatterjee SS; Chambers HF
    Antimicrob Agents Chemother; 2015 May; 59(5):2960-3. PubMed ID: 25753637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Poon H; Chang MH; Fung HB
    Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients.
    Rolston KVI; Jamal M; Nesher L; Raad I; Rice SA; Rybak MJ; Prince RA
    J Glob Antimicrob Resist; 2019 Jun; 17():16-18. PubMed ID: 30844496
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to ceftaroline collected in Russia during 2010-2014.
    Gostev V; Kalinogorskaya O; Kruglov A; Lobzin Y; Sidorenko S
    J Glob Antimicrob Resist; 2018 Mar; 12():21-23. PubMed ID: 29196221
    [No Abstract]   [Full Text] [Related]  

  • 34. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
    Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT
    Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
    Coombs GW; Nimmo GR; Daly DA; Le TT; Pearson JC; Tan HL; Robinson JO; Collignon PJ; McLaws ML; Turnidge JD;
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E309-19. PubMed ID: 25631593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018).
    Sader HS; Jones RN
    Clin Microbiol Infect; 2020 May; 26(5):658-659. PubMed ID: 31899333
    [No Abstract]   [Full Text] [Related]  

  • 39. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.
    Stryjewski ME; Jones RN; Corey GR
    Diagn Microbiol Infect Dis; 2015 Mar; 81(3):183-8. PubMed ID: 25583130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
    Nigo M; Diaz L; Carvajal LP; Tran TT; Rios R; Panesso D; Garavito JD; Miller WR; Wanger A; Weinstock G; Munita JM; Arias CA; Chambers HF
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28232309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.